Anavex Life Sciences Corp.

329 articles about Anavex Life Sciences Corp.

• Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

  5/9/2023

  Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended March 31, 2023.

• Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023Webcast and Conference Call To be Held Tuesday, May 9, 2023, 8:30 am ET

  5/2/2023

  Anavex Life Sciences Corp. today announced that it will issue financial results for its quarter ended March 31, 2023, on Tuesday, May 9, 2023.

• Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

  5/1/2023

  Anavex Life Sciences Corp. announced today it was granted a new U.S. Patent No. 11,622,955 entitled “SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY,” from the United States Patent and Trademark Office.

• Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

  4/25/2023

  Anavex Life Sciences Corp. today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.

• 

  Top 2023 Neurodegenerative Readouts

  4/17/2023

  Clinical results for experimental treatments in Alzheimer’s, ALS and more are expected over the coming months. BioSpace highlights a few of the more highly anticipated datasets.

• Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

  4/10/2023

  Anavex Life Sciences Corp. today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the 22nd Annual Needham Virtual Healthcare Conference 2023 on Monday, April 17, 2023, at 8:00 AM ET.

• ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia

  3/30/2023

  Anavex Life Sciences Corp. reports preliminary 48-week open-label extension Parkinson’s disease dementia ANAVEX®2-73-PDD-EP-001 Phase 2 study data which demonstrated longitudinal beneficial effects of ANAVEX®2-73 on the prespecified primary and secondary objectives, as well as planned primary and key secondary endpoints which will be utilized in a forthcoming pivotal study of ANAVEX®2-73 in Parkinson’s disease.

• Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

  3/9/2023

  Anavex Life Sciences Corp. today announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics.

• Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

  2/7/2023

  Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2022.

• Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

  2/2/2023

  Anavex Life Sciences Corp. today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 ( blarcamesine ) EXCELLENCE Phase 2/3 study in Rett syndrome patients ages ≥ 5 years to 17 (inclusive).

• Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023Webcast and Conference Call To be Held Tuesday, February 7, 2023, 8:30 am ET

  1/31/2023

  Anavex Life Sciences Corp. today announced that it will issue financial results for its quarter ended December 31, 2022 on Tuesday February 7, 2023.

• Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

  12/14/2022

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Prof. Dr. Timo Grimmer, MD, to its Scientific Advisory Board.

• Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

  12/12/2022

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12th 2023.

• 

  CTAD: TauRx Touts Safety Profile as Anavex Stumbles over Data Discrepency (Updated)

  12/2/2022

  TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA.

• ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

  12/2/2022

  Anavex Life Sciences Corp. today announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease.

• Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

  12/2/2022

  Anavex Life Sciences Corp. announced that management will host a conference call on Monday December 5, 2022, at 8:30 am ET to review ANAVEX®2-73-AD-004 Alzheimer’s disease Phase 2b/3 study results.

• Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

  11/28/2022

  Anavex Life Sciences Corp. today reported financial results for its fiscal year ended September 30, 2022.

• Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

  11/23/2022

  Anavex Life Sciences Corp. today announced that it will issue financial results for its fiscal year ended September 30, 2022 on Monday November 28, 2022.

• Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022

  11/8/2022

  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022 on Monday, November 14, 2022, at 11:20 AM ET, to be held at the St. Regis Hotel in New York, NY.

• Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

  11/7/2022

  Anavex Life Sciences Corp. today reports the U.S. Food and Drug Administration’s (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX®2-73 (blarcamesine) for the treatment of Fragile X syndrome.